product name Indoximod (NLG-8189）
Description: Indoximod, also known as NLG8189, and D-1MT (1-Methyl-D-tryptophan), is an IDO pathway inhibitor, it reverses IDO-mediated immune suppression. Indoximod inhibits the enzyme IDO, which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy.
References: Cancer Res. 2007 Jan 15;67(2):792-801; Oncoimmunology. 2012 Dec 1;1(9):1460-1468.
218.25
Formula
C12H14N2O2
CAS No.
110117-83-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 1 mg/mL (4.6 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
1-Methyl-D-tryptophan
other peoduct :
| In Vitro |
In vitro activity: Indoximod significantly reverses the suppression of T cells created by IDO-expressing dendritic cells, using both human monocyte-derived dendritic cells and murine dendritic cells isolated directly from tumor-draining lymph nodes. Indoximod activates a Trp sufficiency signal that stimulates mTOR, and relieves IDO-induced Trp deprivation as well as an autophagic response. Kinase Assay: Cell Assay: The immunosuppressive activity of IDO leads to an increase in the number of T-regulatory cells, as measured by their Foxp3+/CD4+/CD25+ phenotype. Indoximod has also been shown to reduce the number of T-regulatory cells. |
|---|---|
| In Vivo | In mouse models of transplantable melanoma and transplantable and autochthonous breast cancer, Indoximod (400 mg/kg p.o.) enhances antitumor immunity in the setting of combined chemo-immunotherapy regimens. |
| Animal model | Mouse B16F10 and 4T1 tumor models |
| Formulation & Dosage | Dissolved in 0.5% Tween 80/0.5% Methylcellulose (v/v) in water; 400 mg/kg; p.o. administration |
| References | Cancer Res. 2007 Jan 15;67(2):792-801; Oncoimmunology. 2012 Dec 1;1(9):1460-1468. |
